ClinicalTrials.gg
CompletedNCT00191100Updated Aug 11, 2009Results posted

Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix

A Phase 3 interventional study of Gemcitabine and Cisplatin in Cancer of Cervix, sponsored by Eli Lilly and Company. Completed at 7 sites in 7 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-08-11.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing gemcitabine in Uterine Cervical Neoplasms — 4 open to participants now, 4 under way, 3 of them phase 3. Gemcitabine · Uterine Cervical Neoplasms.

Enrollment
Largest of 16
515 · median 95
Started
2002
the only one that year
Phase 3
8 of 18
3 open now
Registered
6th of 18
by date
Lead sponsor
1 of 18
Eli Lilly and Company

Among the 18 studies testing gemcitabine in Uterine Cervical Neoplasms, this one has the largest enrollment of the 16 interventional ones that give a count, is the only one that started in 2002, is one of 8 in phase 3, and was the 6th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 680 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 18 studies testing gemcitabine in Uterine Cervical Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing gemcitabine in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy.

03

Conditions studied

  • Cancer of Cervix
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with cancer of cervix
  • tumor that can be measured
  • no previous treatment with chemotherapy or radiation for this cancer
  • Performance Status Score >=70
  • able to give written consent
  • willing and able to participate in the study, both during the active treatment and the follow-up period.

Exclusion criteria

Exclusion Criteria:

  • impairment such as hearing loss from prior cisplatin therapy
  • damage to nerves such as being unable to distinguish hot and cold to touch
  • used other experimental medication in past 30 days
  • lab test results are not within the limits required for this study
  • pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    1

    Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week Two week rest period with no chemotherapy or radiation Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles

    Drug: Gemcitabine · Drug: Cisplatin · Radiation: Brachytherapy · Radiation: Pelvic radiation

  • Active comparator
    2

    Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week

    Drug: Cisplatin · Radiation: Brachytherapy · Radiation: Pelvic radiation

Interventions

  • Also known as: LY188011, Gemzar

  • RadiationBrachytherapy

    Brachytherapy, 30-35 Gy over 1 week

  • RadiationPelvic radiation

    Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years

    Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted "Measure Type", so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.

    Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively

Secondary outcomes

  1. Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points

    Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.

    Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively

  2. Local Failure Rate

    Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).

    Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively

  3. Tumor Response

    Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.

    Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively

  4. Number of Participants Who Died From Any Cause at Various Time Points

    Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.

    Time frame: baseline to date of death from any cause (includes 60 month follow-up period)

  5. Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points

    Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.

    Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively

07

Results

Posted May 25, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine/Cisplatin/RadiationCisplatin/Radiation
Started259256
Completed217244
Not completed4212
Withdrew: Adverse event181
Withdrew: Lost to follow-up20
Withdrew: Patient moved01
Withdrew: Withdrawal by subject93
Withdrew: Protocol entry criteria not met21
Withdrew: Clinical relapse21
Withdrew: Lack of efficacy, progressive disease12
Withdrew: Lack of efficacy, stable disease10
Withdrew: Physician decision31
Withdrew: Death from study drug toxicity20
Withdrew: Protocol violation11
Withdrew: Death from other cause10
Withdrew: Reason not specified01

Outcome measures

PrimaryNumber of Participants With Progressive Disease or Death Due to Any Cause at 3 Years

Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted "Measure Type", so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.

Time frame:
Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Reported as:
Number · participants
Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years
participantsGemcitabine/Cisplatin/RadiationCisplatin/Radiation
3 Years: Number of Patients with Event5583
3 Years: Number of Patients at Risk149141
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Z Statistic · p = 0.029 (The p-value is two-sided and was tested at the 0.05 significance level.) · Pfs probability difference at 3 years: 0.095 · 95% CI 0.010 to 0.179Difference in progression-free survival probability between Gem/Cis/Rad and Cis/Rad. The difference in PFS probability between the two treatment arms can also be presented as a percentage (ie, PFS at 3 years was 9.5% better in the Gem/Cis/Rad arm).
SecondaryNumber of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points

Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.

Time frame:
Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Reported as:
Number · participants
Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points
participantsGemcitabine/Cisplatin/RadiationCisplatin/Radiation
3 Months: Number of Patients with Event58
3 Months: Number of Patients at Risk221238
6 Months: Number of Patients with Event1025
6 Months: Number of Patients at Risk204218
12 Months: Number of Patients with Event2144
12 Months: Number of Patients at Risk186195
18 Months: Number of Patients with Event2462
18 Months: Number of Patients at Risk176170
24 Months: Number of Patients with Event3169
24 Months: Number of Patients at Risk167158
36 Months: Number of Patients with Event4078
36 Months: Number of Patients at Risk149141
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Log Rank · p = 0.0008
SecondaryLocal Failure Rate

Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).

Time frame:
Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Reported as:
Number · proportion of participants with PD
Local Failure Rate
proportion of participants with PDGemcitabine/Cisplatin/RadiationCisplatin/Radiation
Local Failure Rate0.1130.166
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Fisher Exact · p = 0.096 (The p-value is two-sided and was tested at the 0.05 significance level.)
SecondaryTumor Response

Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.

Time frame:
Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Reported as:
Number · participants
Tumor Response
participantsGemcitabine/Cisplatin/RadiationCisplatin/Radiation
Complete Response223217
Partial Response2220
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Fisher Exact · p = 0.250 (The p-value is two-sided and was tested at the 0.05 significance level.)
SecondaryNumber of Participants Who Died From Any Cause at Various Time Points

Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.

Time frame:
baseline to date of death from any cause (includes 60 month follow-up period)
Reported as:
Number · participants
Number of Participants Who Died From Any Cause at Various Time Points
participantsGemcitabine/Cisplatin/RadiationCisplatin/Radiation
3 Months: Number of Patients with Event30
3 Months: Number of Patients at Risk253254
6 Months: Number of Patients with Event94
6 Months: Number of Patients at Risk241248
12 Months: Number of Patients with Event2225
12 Months: Number of Patients at Risk226222
18 Months: Number of Patients with Event3346
18 Months: Number of Patients at Risk207195
24 Months: Number of Patients with Event3958
24 Months: Number of Patients at Risk200182
36 Months: Number of Patients with Event5375
36 Months: Number of Patients at Risk175158
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Log Rank · p = 0.0224
SecondaryNumber of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points

Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.

Time frame:
Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Reported as:
Number · participants
Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points
participantsGemcitabine/Cisplatin/RadiationCisplatin/Radiation
3 Months: Number of Patients with Event88
3 Months: Number of Patients at Risk221238
6 Months: Number of Patients with Event1425
6 Months: Number of Patients at Risk204218
12 Months: Number of Patients with Event2945
12 Months: Number of Patients at Risk186195
18 Months: Number of Patients with Event3463
18 Months: Number of Patients at Risk176170
24 Months: Number of Patients with Event4272
24 Months: Number of Patients at Risk167158
36 Months: Number of Patients with Event5583
36 Months: Number of Patients at Risk149141
Statistical analysis
  • Gemcitabine/Cisplatin/Radiation vs Cisplatin/Radiation · Log Rank · p = 0.0227

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine/Cisplatin/Radiation———
Cisplatin/Radiation———
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventGemcitabine/Cisplatin/RadiationCisplatin/Radiation
DiarrhoeaGastrointestinal disorders15/2603/255
ThrombocytopeniaBlood and lymphatic system disorders9/2600/255
AnaemiaBlood and lymphatic system disorders6/2600/255
Febrile neutropeniaBlood and lymphatic system disorders6/2601/255
VomitingGastrointestinal disorders6/2604/255
HypokalaemiaMetabolism and nutrition disorders6/2601/255
Vaginal haemorrhageReproductive system and breast disorders5/2605/255
HyponatraemiaMetabolism and nutrition disorders5/2601/255
Abdominal painGastrointestinal disorders4/2601/255
ProctitisGastrointestinal disorders4/2600/255
Most frequent other events
Showing 10 of 35
Most frequent other events
EventGemcitabine/Cisplatin/RadiationCisplatin/Radiation
NeutropeniaBlood and lymphatic system disorders193/26074/255
AnaemiaBlood and lymphatic system disorders175/260115/255
NauseaGastrointestinal disorders167/260155/255
Vaginal haemorrhageReproductive system and breast disorders148/260157/255
DiarrhoeaGastrointestinal disorders159/260131/255
VomitingGastrointestinal disorders146/260121/255
LeukopeniaBlood and lymphatic system disorders145/260114/255
DysuriaRenal and urinary disorders95/26080/255
Abdominal painGastrointestinal disorders87/26057/255
FatigueGeneral disorders80/26057/255

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Mean45.8 ± 9.846.5 ± 9.246.1 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Female259256515.0
Male000.0
Region of Enrollment
Region of Enrollment(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Pakistan272956.0
Mexico283159.0
Argentina171835.0
Thailand343367.0
Peru293160.0
India6056116.0
Bosnia and Herzegovina332861.0
Panama313061.0
Grade of Histological Diagnosis
Grade of Histological Diagnosis(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Moderately Differentiated114119233.0
Poorly Differentiated484492.0
Unknown6969138.0
Undifferentiated202.0
Well Differentiated262450.0
Karnofsky Performance Status Scale
Karnofsky Performance Status Scale(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Unknown (Missing)101.0
70 - Unable to carry on normal activity011.0
80 - Activity with effort; some signs of disease8917.0
90 - Normal activity; minor signs of disease147145292.0
100 - Normal no complaints; no evidence of disease103101204.0
Pathological Diagnosis
Pathological Diagnosis(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Adenocarcinoma of Cervix171532.0
Adeno/Squamous Cell Carcinoma198199397.0
Other - Poorly Differentiated Carcinoma101.0
Other - Squamous434285.0
Race/Ethnicity
Race/Ethnicity(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Western Asian8785172.0
Caucasian332962.0
East/Southeast Asian343367.0
Hispanic105109214.0
Stage of Disease
Stage of Disease(participants)Gemcitabine/Cisplatin/RadiationCisplatin/RadiationTotal
Stage IIIA112.0
Stage IIIB9494188.0
Stage IIB160156316.0
Stage IVA459.0

2 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sarajevo, Bosnia and Herzegovina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Karachi, Pakistan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lima, Peru
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangkok, Thailand
09

References and documents

Publications

  • Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28. PubMed 21444871 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
May 2002
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
May 25, 2009
Last update
Aug 11, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00191100
First posted
Sep 19, 2005
Start date
May 2002
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
May 25, 2009
Last update
Aug 11, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion